Authors
Latest:
Measuring the Value of KOL InteractionsThought leaders are a critical component of a pharmaceutical company?s professional marketing and medical strategies. But companies face a real challenge in creating, maintaining, and leveraging those relationships while safely navigating logistical issues and regulatory waters.
Latest:
Out to Lunch?It's twelve o'clock-do you know where your reps are? According to research from Health Strategies Group, lunches provide one of the few opportunities in today's short-call environment for sit-down discussions with doctors. The average length of a lunch is 13 minutes, with an average of three physicians per meeting.
Latest:
Opinion: Memo to von EschenbachOften, post-approval marketing studies don't materialize because drug companies question their value. Independent review of the need for such studies would address pharma's concern that they may be warranted.
Latest:
Knowledge-Based Outsourcing: Driving Deeper InsightsTracking, monitoring, and trend evaluation is not enough. Companies must now do more than assess what happened and why.
Latest:
The Place of Digital in the Pharma Marketing MixThirty-nine years ago this past June, an article appeared in BusinessWeek that offered readers what was for its time a startling degree of foresight.
Latest:
One Pill Makes You SmallThe obesity pipeline, despite a hugely underserved market potentially worth $11 billion, is awfully thin.
Latest:
Sales Management: Spending Under ScrutinyGiven the high volume of rep interactions with healthcare professionals, companies must work toward achieving a fully integrated system that collects data from across the entire enterprise.
Latest:
Tomorrow’s Selling Strategies: Invest & TestA new PwC survey reveals a strong need to fully embrace alternative commercial methods-not in a blind frenzy but through careful evaluation of which new sales strategies have true innovative potential.
Latest:
Legal: Jumping the PondClass actions threaten industries that deal with the public. If European lawmakers remove the restriction on class-action suits, consumers will be free to file cases. Pharma companies should take heed.
Latest:
Sales Management: The X FactorGen Xers are attractive to many managers because they typically have a strong work ethic. Although they are self-reliant, they still desire to be taken seriously and want to be valued by their companies.
Latest:
Can Data and AI Deliver Whole-Person Health?Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.
Latest:
Pressed Into Action: Measuring Pharma’s Reputation ReversalStudy analyzes mainstream media coverage of the industry before and after the COVID-19 lockdown.
Latest:
More Than a Game of Keep AwayIndustry self-policing may be the only way to stop state Legislators who want to ban sales Reps, and even whole companies, from using Prescribing information.
Latest:
Special Report: Platform Drugs—Marketing Your OpportunitiesTracking business by indication is critical for evaluating market performance and making accurate resource allocations
Latest:
The Diversity Dearth in PharmaWhy the industry needs more women in senior management roles-and the three strategies to get there.
